Mashup Score: 9 FDA approves darolutamide for metastatic castration-sensitive prostate cancer - 4 day(s) ago The approval is supported by data from the pivotal phase 3 ARANOTE trial. Source: www.urologytimes.com Categories: General Medicine News, Urology Tweet Tweets with this article UrologyTimes 🚨BREAKING: The #FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. #mCSPC #pcsm https://t.co/XiHtqW1Pz5
🚨BREAKING: The #FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. #mCSPC #pcsm https://t.co/XiHtqW1Pz5